mirabegron + rifampin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of YM178
Conditions
Pharmacokinetics of YM178
Trial Timeline
Oct 1, 2008 → Dec 1, 2008
NCT ID
NCT00776516About mirabegron + rifampin
mirabegron + rifampin is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of YM178. The current trial status is completed. This product is registered under clinical trial identifier NCT00776516. Target conditions include Pharmacokinetics of YM178.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00776516 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of YM178